First Trust Advisors LP Takes $1.72 Million Position in Humacyte, Inc. (NASDAQ:HUMA)

First Trust Advisors LP acquired a new position in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 340,552 shares of the company's stock, valued at approximately $1,720,000. First Trust Advisors LP owned about 0.27% of Humacyte as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock worth $28,294,000 after buying an additional 543,995 shares during the last quarter. Barclays PLC boosted its holdings in Humacyte by 177.6% in the 3rd quarter. Barclays PLC now owns 236,742 shares of the company's stock valued at $1,288,000 after purchasing an additional 151,458 shares during the period. Brookstone Capital Management acquired a new stake in Humacyte in the 4th quarter worth $56,000. Wealth Effects LLC increased its holdings in shares of Humacyte by 89.1% during the 4th quarter. Wealth Effects LLC now owns 121,400 shares of the company's stock worth $613,000 after purchasing an additional 57,200 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Humacyte during the fourth quarter valued at about $99,000. Institutional investors own 44.71% of the company's stock.

Humacyte Trading Down 1.7 %

Shares of Humacyte stock traded down $0.02 during mid-day trading on Friday, reaching $1.19. 2,020,672 shares of the stock were exchanged, compared to its average volume of 3,630,465. The company has a market cap of $184.59 million, a price-to-earnings ratio of -0.89 and a beta of 1.64. Humacyte, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $9.97. The firm has a 50-day simple moving average of $1.99 and a 200 day simple moving average of $3.65.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings data on Friday, March 28th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.07. The company had revenue of $7.23 million for the quarter, compared to the consensus estimate of $0.64 million. On average, research analysts predict that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Benchmark restated a "buy" rating on shares of Humacyte in a research note on Thursday, February 27th. D. Boral Capital restated a "buy" rating and issued a $25.00 target price on shares of Humacyte in a research note on Wednesday, March 26th. Finally, HC Wainwright reiterated a "buy" rating and set a $15.00 price target on shares of Humacyte in a research note on Wednesday, March 12th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $13.71.

Insider Buying and Selling

In other Humacyte news, CFO Dale A. Sander bought 20,000 shares of Humacyte stock in a transaction dated Thursday, April 10th. The shares were bought at an average price of $1.53 per share, with a total value of $30,600.00. Following the purchase, the chief financial officer now owns 40,600 shares of the company's stock, valued at $62,118. This trade represents a 97.09 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Kathleen Sebelius purchased 50,000 shares of the stock in a transaction dated Tuesday, April 8th. The shares were acquired at an average price of $1.32 per share, with a total value of $66,000.00. Following the transaction, the director now owns 91,207 shares in the company, valued at $120,393.24. This trade represents a 121.34 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 83,993 shares of company stock worth $118,224 in the last quarter. Insiders own 11.20% of the company's stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.